[1] WLI performs pre-formulation and formulation work, consulting, pharmacokinetics support, in-vitro ADME screens, analytical characterization of API, stability testing and other contract research.

[2] Conducted by the Commonwealth Institute and Center for Woman's Leadership at Babson College, the top 100 businesses were identified based on company revenue.

As late as the 1990s, inadequate appreciation for the translational phase of development led to investment in drug candidates with poor or unsuitable physicochemical and ADME properties.

WLI also identifies and addresses various issues affecting the safety of a drug for human consumption, such as ADME characteristics like inadequate bioavailability, interference (activation or inhibition) with the Cytochrome P450 complex and unsuitable clearance profiles.

[5] WLI specializes in complex cases where excipients must be used to make compounds soluble, a necessary step for clients to advance their products to in vivo trials.